Last reviewed · How we verify
Anplag (SARPOGRELATE)
Anplag (generic name: SARPOGRELATE) is a sarpogrelate drug. It is currently in Phase 3 development.
Anplag works by blocking the 5-hydroxytryptamine receptor 2A, which helps to relax blood vessels and improve blood flow.
Anplag, also known as Sarpogrelate, is a small molecule serotonin 2a (5-HT2a) receptor antagonist. It has been studied in clinical trials for various conditions, including Diabetic Nephropathy, Hypertension, Peripheral Artery Disease, Coronary Artery Disease, and Chronic Kidney Disease.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | SARPOGRELATE |
|---|---|
| Drug class | sarpogrelate |
| Target | 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
Imagine your blood vessels are like roads in your body. When they constrict, it's like a traffic jam. By blocking the 5-hydroxytryptamine receptor 2A, Anplag helps to relax the blood vessels, allowing blood to flow more easily and reducing the risk of conditions like Raynaud's disease.
Approved indications
Common side effects
- Interstitial lung disease
- Hepatic function abnormal
Key clinical trials
- A Study to Compare the Effects of Sarpogrelate Sustained Release /Aspirin Combination Therapy Versus Aspirin on Blood Viscosity in the Patients With Peripheral Arterial Disease and Coronary Artery Disease (PHASE4)
- Multicenter, Therapeutic Use Observational Study to Evaluate the Effects of Concurrent Therapy of Sarpogrelate
- Comparison of the Improvement and Safety of the Ankle Brachial Arterial Pressure Index of Sarpogrelate and Clopidogrel in Stroke Patients With Decreased Ankle Brachial Arterial Pressure Index and Intermittent Claudication of Lower Limb Vascular Atherosclerosis. (NA)
- Clinical Trial to Evaluate the Efficacy and Safety of Sarpogrelate SR in Patients With Chronic Artery Occlusive Disease (PHASE4)
- Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study) (PHASE4)
- A Study to Evaluate the Effect of Sarpogrelate on Blood Hyperviscosity (PHASE4)
- Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fasting Conditions (PHASE1)
- Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fed Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anplag CI brief — competitive landscape report
- Anplag updates RSS · CI watch RSS
Frequently asked questions about Anplag
What is Anplag?
How does Anplag work?
What is the generic name of Anplag?
What drug class is Anplag in?
What development phase is Anplag in?
What are the side effects of Anplag?
What does Anplag target?
Related
- Drug class: All sarpogrelate drugs
- Target: All drugs targeting 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C
- Therapeutic area: All drugs in Hematology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing